Pfizer and Flynn accused of overcharging NHS for anti-epilepsy drugs

Pharmaceutical companies ファイザー and Flynn have been accused by the UK’s competition watchdog of illegally overcharging the NHS for vital anti-epilepsy drugs by abusing their dominance in the market to raise prices overnight.

競争市場庁 (CMA) has confirmed its 2016 finding that the pair exploited a loophole to charge unfairly high prices for phenytoin sodium capsules by debranding the drug, known as Epanutin, に 2012 so it would not face price regulation.

ザ・ watchdog began reassessing the case after the drugs maker Pfizer appealed against the CMA’s 2016 fine of £84.2m – a record at the time – for raising the cost of the anti-epilepsy drug by up to 2,600%. Flynn Pharma, a drugs distributor, faced a fine of £5.2m for charging excessive and unfair prices for phenytoin sodium capsules.

Although the Competition Appeal Tribunal (CAT) upheld parts of the watchdog’s findings, it referred the matter of whether Pfizer and Flynn abused their market position back to the CMA for further consideration.

The CMA said after carefully assessing further evidence it believes that the pair were able to abuse their dominant position to overcharge the NHS, by debranding the capsules which are used by an estimated 48,000 epilepsy patients in the UK to prevent and control seizures.

According to the CMA’s provisional findings the overnight price rise meant the NHS spending on the drug soared from £2m a year in 2012 to about £50m in 2013. For over four years, Pfizer’s prices were between 780% そして 1,600% higher than it had previously charged. Pfizer then supplied the drug to Flynn which charged prices between 2,300% そして 2,600% higher than those they had paid previously.

“Thousands of patients depend on this drug to prevent life-threatening seizures as a result of their epilepsy,” the CMA chief executive, Andrea Coscelli, 前記. “Protecting these patients, the NHS and the taxpayers who fund it, is our priority.”

Pfizer and Flynn have an opportunity to respond to the CMA’s provisional findings before the regulator reconsiders whether they broke the law. The companies were not immediately available for comment.

In recent weeks the CMA has fined a string of pharma companies linked to Auden Mckenzie and Actavis UK, now known as Accord-UK, a total of 260m for inflating the price of hydrocortisone, which is used by tens of thousands of people in the UK to treat adrenal insufficiency, which includes life-threatening conditions such as Addison’s disease.

It also imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its liothyronine tablets, which are used to treat thyroid hormone deficiency, by up to 6,000%.